GB0128287D0 - Novel method and compounds - Google Patents

Novel method and compounds

Info

Publication number
GB0128287D0
GB0128287D0 GBGB0128287.0A GB0128287A GB0128287D0 GB 0128287 D0 GB0128287 D0 GB 0128287D0 GB 0128287 A GB0128287 A GB 0128287A GB 0128287 D0 GB0128287 D0 GB 0128287D0
Authority
GB
United Kingdom
Prior art keywords
compounds
novel method
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0128287.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to GBGB0128287.0A priority Critical patent/GB0128287D0/en
Publication of GB0128287D0 publication Critical patent/GB0128287D0/en
Priority to AU2002352142A priority patent/AU2002352142A1/en
Priority to PCT/EP2002/013261 priority patent/WO2003045949A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
GBGB0128287.0A 2001-11-26 2001-11-26 Novel method and compounds Ceased GB0128287D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB0128287.0A GB0128287D0 (en) 2001-11-26 2001-11-26 Novel method and compounds
AU2002352142A AU2002352142A1 (en) 2001-11-26 2002-11-25 Pyrazolopyridine derivatives
PCT/EP2002/013261 WO2003045949A1 (en) 2001-11-26 2002-11-25 Pyrazolopyridine derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0128287.0A GB0128287D0 (en) 2001-11-26 2001-11-26 Novel method and compounds

Publications (1)

Publication Number Publication Date
GB0128287D0 true GB0128287D0 (en) 2002-01-16

Family

ID=9926458

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0128287.0A Ceased GB0128287D0 (en) 2001-11-26 2001-11-26 Novel method and compounds

Country Status (3)

Country Link
AU (1) AU2002352142A1 (en)
GB (1) GB0128287D0 (en)
WO (1) WO2003045949A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2851247B1 (en) 2003-02-19 2007-06-29 Exonhit Therapeutics Sa METHODS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DEGENERATIVE PATHOLOGIES
DE602004014372D1 (en) 2003-06-17 2008-07-24 Pfizer N-PYRROLIDIN-3-YL-AMIDE DERIVATIVES AS INHIBITORS OF SEROTONIN AND NORADRENALINE RECOVERY
FR2856595B1 (en) * 2003-06-27 2008-05-30 Exonhit Therapeutics Sa METHODS AND COMPOSITIONS FOR TREATING COGNITIVE DEFICITS.
BRPI0411122A (en) * 2003-06-27 2006-07-18 Pfizer Prod Inc pyrazol [3,4-b] pyridin-6-ones as gsk-3 inhibitors
JP4680897B2 (en) * 2003-06-27 2011-05-11 ファイザー・プロダクツ・インク Pyrazolo [3,4-B] pyridin-6-ones as GSK-3 inhibitors
US7709645B2 (en) 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7626021B2 (en) 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
EP1778687A2 (en) 2004-07-27 2007-05-02 SGX Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
NZ553267A (en) 2004-07-27 2010-09-30 Sgx Pharmaceuticals Inc Pyrrolo-pyridine kinase modulators
US7361764B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
PE20061119A1 (en) * 2005-01-19 2006-11-27 Aventis Pharma Sa PYRAZOLO PYRIDINES SUBSTITUTED AS INHIBITORS OF FAK, KDR AND Tie KINASES
FR2888579A1 (en) * 2005-07-13 2007-01-19 Aventis Pharma Sa New pyrazole substituted pyridine compounds are kinase inhibitors, useful as an inhibiting agent for kinase-catalyzed reaction and for the manufacture of a drug to treat cancer
US7541367B2 (en) 2005-05-31 2009-06-02 Janssen Pharmaceutica, N.V. 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
FR2889526B1 (en) 2005-08-04 2012-02-17 Aventis Pharma Sa SUBSTITUTED 7-AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PROCESS FOR PRODUCTION AND USE
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
CN101365700A (en) 2005-11-15 2009-02-11 沃泰克斯药物股份有限公司 Azaindazoles useful as inhibitors of kinases
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CA2670418A1 (en) * 2006-11-24 2008-05-29 Ac Immune Sa N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers's
BRPI0810496A2 (en) * 2007-04-09 2018-11-06 Hoffmann La Roche non-nucleoside reverse transcriptase inhibitors
KR20090031122A (en) * 2007-09-21 2009-03-25 주식회사 중외제약 Compounds containing indazole frameworks, preparing method thereof and pharmaceutical composition containing thereof
KR20100093552A (en) 2007-11-02 2010-08-25 버텍스 파마슈티칼스 인코포레이티드 [1h-pyrazolo[3,4-b]pyridine-4-yl]-phenyle or -pyridin-2-yle derivatives as protein kinase c-theta
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2311823A1 (en) 2009-10-15 2011-04-20 AC Immune S.A. 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
KR20120063283A (en) * 2010-12-07 2012-06-15 제일약품주식회사 Novel pyrazolopyridine derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same
WO2012135631A1 (en) * 2011-03-30 2012-10-04 Arrien Pharmaeuticals Llc Substituted 5-(pyrazin-2-yl)-1h-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors
WO2016004272A1 (en) 2014-07-02 2016-01-07 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
JP2022520671A (en) 2019-02-08 2022-03-31 フリークエンシー・セラピューティクス・インコーポレイテッド Valproic acid compounds and WNT agonists for the treatment of ear disorders
KR102580387B1 (en) * 2021-05-07 2023-09-19 한국화학연구원 Pharmaceutical compositions comprising novel pyrazolo[3,4-b]pyridine derivatives for preventing or treating metabolic diseases including obesity and diabetes mellitus, or nonalcholic steatohepatitis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL106896B1 (en) * 1978-01-03 1980-01-31 METHOD OF MAKING NEW BIOLOGICALLY ACTIVE PYRAZOLO- / 3,4-B / -pyridine DERIVATIVES
DK0765327T3 (en) * 1994-06-16 1999-11-29 Pfizer Pyrazolo and pyrrolopyridines
AU2001287898A1 (en) * 2000-09-22 2002-04-02 Stephen Garland Pyrazolopyridines and pyrazolopyridazines as antidiabetics

Also Published As

Publication number Publication date
WO2003045949A1 (en) 2003-06-05
AU2002352142A1 (en) 2003-06-10

Similar Documents

Publication Publication Date Title
GB0128287D0 (en) Novel method and compounds
GB0109993D0 (en) Method
GB0118251D0 (en) Method
EP1434772A4 (en) Compounds and methods
GB0122049D0 (en) Method
GB0109049D0 (en) Method
AU2002359694A8 (en) Compounds and methods
GB0115243D0 (en) Method
GB0103998D0 (en) Method
GB0116453D0 (en) Method
GB0126531D0 (en) Method
GB0114629D0 (en) Method
EP1379240A4 (en) Compounds and methods
GB0101762D0 (en) Method
GB0108349D0 (en) Method
GB0110547D0 (en) Method
GB0101763D0 (en) Method
GB0116142D0 (en) Method
GB0119009D0 (en) Compound and process
GB0111987D0 (en) Method
GB0119339D0 (en) Method
GB0102947D0 (en) Method
GB0125793D0 (en) Method
GB0111206D0 (en) Novel method and compounds
GB0108974D0 (en) Novel method and compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)